Apelin
As of the edition of 20 October 2026, Apelin is a drug: in active development; acts on APLNR.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2018
- Kind
- Unknown
- Registered trials
- 10, 0 stopped early
- Disease areas
- Heart and blood vessels; Nutrition and metabolism; Hormones; Lungs and airways; Nervous system
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| APLNR | Apelin receptor | P35414 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 5 | 4 | 0 | 0 |
| Phase 1 | 4 | 4 | 0 | 0 |
| Phase 2 | 1 | 0 | 0 | 0 |
| All trials | 10 |